Editorial

DOI: 10.4244/EIJ-E-22-00054

Periprocedural adverse events after revascularisation: the importance of getting off to a good start

Mario Gaudino1, MD, PhD; Arnaldo Dimagli1, MD
In this issue of the journal, Kotoky et al shed light on the association between periprocedural major adverse events (PMAE) and long-term mortality in patients undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in a post hoc analysis of the SYNTAX trial1. The authors should be congratulated for this important work and the food for thought it provides.

PMAE were defined as a composite of numerous periprocedural complications occurring within 30 days from the index procedure. Patients undergoing CABG were more likely to experience one of these events than those undergoing PCI (28.2% vs 11.2%; p<0.001). This difference was mainly driven by the higher incidence of major infections and arrhythmias in the CABG group. It should be noted that this trial enrolled patients between 2005 and 2008, and this difference may not hold true nowadays. For example, our group has recently shown how the incidence of postoperative atrial fibrillation (the most common complication of CABG) can be halved by left posterior pericardiotomy2.

Regardless of the merit of the single procedure (CABG or PCI), PMAE were associated with an increased risk of all-cause mortality at 1 year, but not at 5 and 10 years. This important time-dependency offers the reader two essential messages: first, the need for a tailored, stricter follow-up for patients developing PMAE after an intervention; second, the potential role of optimal medical therapy (OMT). Indeed, the authors found that in patients with PMAE on OMT, there was a lower risk of all-cause mortality compared to patients with PMAE but not on OMT. This is not surprising considering the findings of a meta-analysis of 5 randomised clinical trials that showed that increasing compliance to OMT significantly improved outcomes following CABG and PCI3.

On one hand, the lack of association between PMAE and mortality at 5 and 10 years can be reasonably explained by the fact that the effects of those events are more evident early after their occurrence and then diminish. On the other hand, readers should consider the combination of three factors: a relatively old cohort of patients; long follow-up; and use of non-cause-specific mortality as an outcome. This combination may have biased and actually underestimated the association investigated at long-term follow-up.

Another important message revolves around the definition for the diagnosis of periprocedural myocardial infarction (MI), which has been debated at length in recent years4. In this post hoc analysis, besides the original definition used in the SYNTAX trial, the authors presented further analyses using different definitions and found consistent results across all definitions. This highlights the clinical relevance of post-revascularisation myonecrosis irrespective of the definition used, also considering that, among PMAE, MI was the only event retaining an association with mortality up to 10 years when considered singularly. It is possible that some periprocedural complications are more prone to increase the periprocedural mortality risk but, once resolved, do not influence long-term risks, while others, such as MI, are able to carry a substantial risk throughout the years.

Surprisingly, the authors did not find infections, in particular after CABG, to be associated with a higher risk of mortality at 5 and 10 years. This is in contrast with previous studies and a meta-analysis showing that a sternal wound infection is a risk factor for long-term mortality56. This difference could be related to the smaller CABG sample size in this post hoc analysis.

Another important thought-provoking finding is the miscalibration of the SYNTAX score II. In recent years, there has been an increasingly higher focus on the ability to predict not only short-term outcomes, as is already quite well done by the EuroSCORE and STS score7, but also long-term outcomes. In this regard, the authors showed a notable underestimation of risk by the SYNTAX score II in the cohort of patients experiencing PMAE. This underlines the reasonable assumption that long-term prediction cannot rely exclusively on preprocedural variables but also needs to take into account operative and post-procedural events that can impact patients’ long-term recovery. This assumption is further supported by the finding that patients who experienced more than two PMAE were associated with lower survival up to 10 years.

In conclusion, this is a significant contribution, filling a gap in the evidence and providing cardiologists and surgeons with important information: periprocedural events should trigger a tailored, more aggressive follow-up accompanied by optimisation of medical therapy to guarantee the best outcomes for the patients.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 18 Number 15
Mar 20, 2023
Volume 18 Number 15
View full issue


Key metrics

On the same subject

Clinical research

10.4244/EIJ-D-22-00681 Mar 20, 2023
Impact of periprocedural major adverse events on 10-year mortality after revascularisation
Kotoku N et al
free

Editorial

10.4244/EIJ-E-23-00004 Mar 20, 2023
Revascularisation, periprocedural events and survival – and the survival of the randomised controlled trial
Lansky AJ and Ahmad Y
free

10.4244/EIJV15I17A269 Apr 17, 2020
Major infections after bypass surgery and stenting: an overlooked but fatal complication
Harari R and Bangalore S
free

Short report

10.4244/EIJ-D-20-00170 May 16, 2021
Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy
Takahashi K et al
free

Clinical research

10.4244/EIJ-D-19-00208 Apr 17, 2020
Major infections after bypass surgery and stenting for multivessel coronary disease in the randomised SYNTAX trial
Mancone M et al
free

Editorial

10.4244/EIJ-E-22-00008 Apr 22, 2022
SYNTAXES, biomarkers and survival in complex coronary artery disease: the intervention of secondary prevention
Gulati M and Burgess S
free
Trending articles
337.28

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
284.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
226.03

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
209.5

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.15

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
150.28

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved